Article

How Many Opioids Have Received ADP Designation on the Basis of Category 1 Studies Alone?

Conference|PAINWeek Conference

J. David Haddox, DDS, MD, corrects a misconception about opioids with abuse-deterrent properties.

J. David Haddox, DDS, MD, corrects a misconception about opioids with abuse-deterrent properties.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Hematology -- Image credit: DIgilife | stock.adobe.com
Related Content
elbow bones injury - Image credit: SoftSheep | stock.adobe.com
July 15th 2025

Type 2 Diabetes and Obesity in Teens Could Increase Risk of Osteoporosis

Kennedy Ferruggia, Assistant Editor
Pharmacy Focus: Importance of Mental Health for Patients and Pharmacists Alike
July 10th 2025

Pharmacy Focus: Importance of Mental Health for Patients and Pharmacists Alike

Gustavo Alva, MD Luke Halpern, Assistant Editor
Insulin and syringe | Image Credit: © Sherry Young - stock.adobe.com
July 15th 2025

Insulin Aspart-xjhz Becomes First Interchangeable Biosimilar Rapid-Acting Insulin

Alexandra Gerlach, Associate Editor
Pharmacy Focus: Navigating Seasonal Allergies
May 28th 2025

Pharmacy Focus: Navigating Seasonal Allergies

Luke Halpern, Assistant Editor Derek Webb, PharmD
Respiratory Virus Genetic Material Micrograph - Image credit: GOLVR | stock.adobe.com
July 15th 2025

Targeting the Integrated Stress Response Through a Platform for Antiviral Drug Discovery Against Zika, Herpes, and RSV

Kennedy Ferruggia, Assistant Editor
Types of diabetes
July 15th 2025

Finerenone and the Future of Diabetes-Related Kidney Care

Andy Dang, PharmD Candidate Natalie Rosario, PharmD, MPH, BCACP Elisabeth M. Wang, PharmD, BCCP Shantera Davis, PharmD, BCPS K’bria Whaley, PharmD Candidate Joshua Wollen, PharmD